Technology

Smartkem Announces Uplisting to Nasdaq

Published

2 years ago

May 30, 2024

MANCHESTER, England, May 30, 2024 /PRNewswire/ — Smartkem, Inc. (OTCQB: SMTK; NASDAQ: SMTK) (the “Company” or “Smartkem”), the developer of a new class of semiconductor polymer transistors with the potential to power the next generation of displays, announced today that the Company has received approval to list its common stock on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “SMTK”. Trading on Nasdaq is expected to commence with the open of trading on Friday, May 31st. Shareholders are not required to take any action as a result of the uplisting.

Smartkem Chairman and Chief Executive Officer, Ian Jenks, comments, “Smartkem’s uplist from the OTCQB to Nasdaq is a significant achievement for the Company. We believe that the Nasdaq listing will result in increased marketability, liquidity, and trading volume, and provide the Company with increased access to the capital markets as we work to provide long-term value for our stockholders.”

Smartkem’s OTCQB information can be found on the OTC Markets website: www.otcmarkets.com/stock/SMTK/overview

About Smartkem
Smartkem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to drive the next generation of displays. Smartkem’s patented TRUFLEX® semiconductor and dielectric inks, or liquid electronic polymers, can be used to make a new type of transistor that has the potential to revolutionize the display industry. Smartkem’s inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing technology. The company’s electronic polymer platform can be used in a number of display technologies including microLED, miniLED and AMOLED displays for next generation televisions, laptops, augmented reality (AR) and virtual reality (VR) headsets, smartwatches and smartphones.

Smartkem develops its materials at its research and development facility in Manchester, UK and provides prototyping services at the Centre for Process Innovation (CPI) at Sedgefield, UK, It has a field application office in Taiwan. The company has an extensive IP portfolio including 125 granted patents across 19 patent families and 40 codified trade secrets. For more information, visit: www.Smartkem.com and follow us on LinkedIn www.linkedin.com/company/Smartkem-limited and Twitter @SmartkemOTFT.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Smartkem’s expectations regarding the effect of the Nasdaq listing on its common stock, its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on Smartkem Inc.’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or elated expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View original content:https://www.prnewswire.co.uk/news-releases/smartkem-announces-uplisting-to-nasdaq-302160116.html

Technology

IGCS International Announces Strategic Equity Investment by Lacks Enterprises

Published

27 minutes ago

April 22, 2026

DALLAS, April 22, 2026 /PRNewswire/ — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, russ@igcsintl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/igcs-international-announces-strategic-equity-investment-by-lacks-enterprises-302750824.html

SOURCE IGCS International

Technology

Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

Published

27 minutes ago

April 22, 2026

GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-report-first-quarter-2026-financial-results-on-may-13-2026-302750154.html

SOURCE Shoulder Innovations

Technology

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Published

27 minutes ago

April 22, 2026

MADISON, Wis., April 22, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.html

SOURCE Accuray Incorporated